Article

Eyeonics clarifies lens will treat presbyopia

Aliso Viejo, CA-Eyeonics Inc. is altering the wording of the physician's labeling on its Crystalens IOL to indicate better that it can treat presbyopia.

Aliso Viejo, CA-Eyeonics Inc. is altering the wording of the physician's labeling on its Crystalens IOL to indicate better that it can treat presbyopia.

The wording previously did not specify that patients with presbyopia would benefit, but a number of clinical Web sites have included that in their explanations of the lens and refractive lensectomy.

The new label indicates that the Crystalens is intended for primary implantation in the capsular bag for the correction of aphakia "secondary to the removal of a cataractous lens in adult patients with and without presbyopia."

"Prospective patients will realize that they are going to receive a new technologically advanced lens that replaces their dysfunctional natural lens as well as providing them a viable option to restore their continuous range of vision that they enjoyed earlier in life," he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.